MSM Prep study to kick off in Cape Town
Prep is a therapy taken to prevent, rather than to treat, an infection or illness, and it is one strategy being studied by the University of Cape Town’s Desmond Tutu HIV Foundation, as part of its effort to develop new HIV prevention tools.
This study is designed to determine whether a once daily oral dose of the HIV antiretroviral drug Truvada (tenofovir disoproxil fumarate and emtricitabine) will provide additional protection against HIV infection when combined with risk reduction and condom use counseling.
The study will enroll 200 healthy, sexually active, HIV-negative men who have sex with men (MSM) who are at high risk of HIV infection. Potential volunteers will be extensively interviewed to ensure that they understand the study and that their participation is completely voluntary. Consenting study participants will be carefully monitored throughout the 24-month study period and for 6 months afterwards. All study participants will receive condoms and counseling on how to prevent HIV infection, and medical care for any sexually transmitted infections on a monthly basis.
Approximately half will also receive the study drug Truvada once daily, and half will receive a placebo. Neither the study personnel nor the volunteers will know who is receiving the drug and who is receiving placebo. In addition to extensive safer sex counseling, volunteers will be counseled that, even if they receive the study drug, there is no assurance that the drug will offer any protection against HIV infection and that safer sex precautions should always be used.
Truvada was selected for the Cape Town Prep study because it has been shown to be a safe and effective treatment for HIV, with few side effects in studies involving more than 15 000 people worldwide. The tenofovir plus emtricitabine drug combination of Truvada was approved for use by the Food and Drug Administration in the United States in 2004, and in South Africa by the Medicine Control Council in 2007. More than 100 000 HIV-infected people around the world have now used these drugs.
The National Institutes of Health and the Bill and Melinda Gate Foundation are sponsoring the Cape Town Prep study through a grant to the J. David Gladstone Institutes, a non-profit independent research organization affiliated with the University of California, San Francisco.
The Desmond Tutu HIV Foundation is a registered non-profit organization that has developed a robust HIV prevention research agenda focusing on disenfranchised population – particularly young women and MSM.
Author
-
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
MSM Prep study to kick off in Cape Town
by healthe, Health-e News
July 22, 2008